GlassScriptPhysician profile
Caren G Marks
NPI 1174507644
$11,506.32
in general payments reported to CMS, 2019-2025
28 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $1,041 · 2021: $718 · 2022: $928 · 2023: $1,914 · 2024: $2,490 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,865 · Consulting Fee: $150 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,864.67 |
| Consulting Fee | $150.00 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,446.38 | 2019-2025 | |
| Biogen, INC. | $1,896.17 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Emd Serono, INC. | $1,588.86 | 2019-2025 | Mavenclad |
| Genzyme Corporation | $968.23 | 2019-2025 | |
| Genentech USA, INC. | $706.94 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Abbvie INC. | $702.06 | 2021-2025 | |
| Tg Therapeutics, INC. | $591.32 | 2023-2025 | |
| Celgene Corporation | $566.47 | 2019-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $306.10 | 2021-2023 | Ponvory |
| Amgen INC. | $276.39 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $206.64 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $164.62 | 2022-2025 | Vyepti |
| Mallinckrodt Hospital Products INC. | $141.00 | 2020-2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $140.56 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $124.42 | 2024-2025 | Ponvory |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $118.24 | 2020 | |
| Horizon Therapeutics Plc | $117.81 | 2021-2023 | Uplizna |
| Ani Pharmaceuticals, INC. | $101.65 | 2024-2025 | Purified Cortrophin Gel |
| Avanir Pharmaceuticals, INC. | $86.19 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $43.00 | 2023 | Nuedexta |
| Acorda Therapeutics, INC | $42.33 | 2019-2023 | Ampyra |
| Mallinckrodt Enterprises LLC | $42.17 | 2019 | |
| Merz Pharmaceuticals, LLC | $35.53 | 2024-2025 | Ampyra, Xeomin |
| Ipsen Biopharmaceuticals, INC | $27.37 | 2019 | |
| Medtronic USA, INC. | $18.88 | 2019 | |
| Banner Life Sciences, LLC | $16.83 | 2022 | |
| Axsome Therapeutics, INC. | $15.69 | 2023 | Sunosi |
| Cycle Pharmaceuticals INC | $14.47 | 2025 | Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caren Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.